501O_PR Epidemiology, real world treatment and outcomes of 423 patients (pts) with angiosarcoma (AS) in Asia: A report from the Asian Sarcoma Consortium (ASC)

Quek, Richard; Loong, Herbert H.; Sriuranpong, Virote; Farid, Mohamad; Tan, Sze Huey; Goh, Wei Lin; Mingmalairak, Siyamol; Chen, T.W-W.; Cc, Chang; Pang, Angela; Teo, Sharon; Puhaindran, Mark E.; Maw, Myo; Ngan, Roger K.C.; Leung, A. K. C.; Chan, Jeffrey; Hirose, Toshiharu; Kawai, Akira

doi:10.1093/annonc/mdw597.001

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preliminary sessions aimed at setting the knowledge base for each selected topic b. Handled by an assigned faculty from the ASC c. 30-40-minute presentations followed by [5][6][7][8][9][10] minutes for open forum d. Prior to the start of all activities, all participants completed a 20-item MCQ pre-test.…”

Section: Educational Activities Utilizedmentioning

confidence: 99%

See 1 more Smart Citation

The Asian Sarcoma Consortium Sarcoma Preceptorship Program: A Program Evaluation Study Utilizing the Kirkpatrick Model (Level 1 and 2)

2022

Acta Med Philipp

View full text Add to dashboard Cite

Background. Sarcomas, a heterogenous group of malignancies consisting of tumors, are rarely encountered in most general oncology clinics. As a result, most general oncologists have very little experience in dealing with these tumors and resulting in poorer treatment and survival outcomes. Having successful collaborative efforts in research, the Asian Sarcoma Consortium (ASC) pioneered a Sarcoma Preceptorship Program with its main goal of increasing awareness of the multidisciplinary approach in the management of sarcomas.Objective. The objective of this study is to evaluate the ASC Sarcoma Preceptorship Program using the first 2 levels of the Kirkpatrick Evaluation Model: Level 1) Reaction -through using satisfaction surveys; and Level 2) Knowledge -focusing on the amount of information gained from the activity evaluated by test-retest method.Methods. The 2-day preceptorship program held in Singapore utilized educational activities such as didactic lectures, multidisciplinary case discussions, and case presentations. The program was evaluated using: 1) pre-test and posttest; 2) satisfaction survey from ASC; and 3) satisfaction survey made by the sponsor, Novartis Pharma.Results. The preceptorship program enrolled 30 participants, most from the Asia-Pacific region. The overall results from the satisfaction surveys were generally optimistic, with results showing high levels of satisfaction with regard to the time allotment, scope of topics, and how helpful each session was. Test results showed that participants scored lower in post-test as compared to the pre-test. Computation of the Coefficient of Test reliability showed that although the pre-test was highly reliable, this was not true of the post-test. Conclusions.Based on the Level 1 evaluation, the program was successful in terms of both participant and faculty satisfaction. However, certain areas for improvement were identified and recommendations were made in order to effect improvements for future iterations of this preceptorship.

show abstract

Section: Educational Activities Utilizedmentioning

confidence: 99%

“…This collaborative effort has proven to be very successful, with the ASC presenting its first research output on Angiosarcoma at the ESMO Asia Conference in December 2016. This consists of 2 projects on Angiosarcoma 7,8 , both of which were presented in paper presentation sessions and were well-received.…”

Section: Introductionmentioning

confidence: 99%

The Asian Sarcoma Consortium Sarcoma Preceptorship Program: A Program Evaluation Study Utilizing the Kirkpatrick Model (Level 1 and 2)

2022

Acta Med Philipp

View full text Add to dashboard Cite

show abstract

“…In this respect the Asian Sarcoma Consortium (ASC), was formed to bring together the Asian sarcoma research community. In its inaugural efforts, the group reported on the epidemiology and real world treatment of a large cohort of 423 patients with angiosarcoma from 8 sites in 6 Asian countries (69). Additionally the STAR study (5) was an Asian multi-centred observational study initiated to describe epidemiology, treatment patterns and clinical outcomes in STS patients diagnosed between 2006-2010.…”

Section: Research Collaborationmentioning

confidence: 99%

Soft tissue sarcoma in Asia

Poon¹,

Quek²

2018

Chin. Clin. Oncol.

View full text Add to dashboard Cite

Sarcoma is an uncommon and heterogeneous group of malignancies linked by their mesenchymal origin. They are rare and account for 1% of adult cancers, and 10-20% of adolescent and young adult (AYA) cancers. While there is good published literature on the incidence and distribution of sarcoma subtypes in the western populations, there is a paucity of data from Asia, particularly on the epidemiology, treatment and outcomes of STS in Asia. Formalized prospective national registries in soft tissue sarcoma (STS) are lacking and little is known about how sarcomas are treated and managed throughout the Asia-Pacific region. Due to geographical and varying affluence levels across over 50 countries, no single uniform guideline exists across Asia to inform of chemotherapeutic options. Any existent guidelines tend to be country-specific, reflecting resource availability and geographical limitation. To understand and improve STS care in Asia, one must appreciate the macroeconomics and healthcare structures in place and to work within the limitations imposed by them. Concurrently, there exists an urgency to develop strong sarcoma centres of excellence (SCE) across Asia to deliver state-of-art care to our patients. Equally important is the need to facilitate sarcoma education to patients and healthcare workers. Development of such centres is vital in improving clinical care as they provide high-quality sub-specialized care to patients within that geographical location, serve as reference centres for knowledge and education as well as nerve centres for care-coordination in a hub-and-spoke model. Key to these centres of excellence is the sarcoma multi-disciplinary team (MDT). Studies have consistently shown that patients managed in high-volume sarcoma centres, by an expert sarcoma MDT, achieve better clinical outcomes. This report serves to highlight the challenges and opportunities of sarcoma care in Asia, map out a vision for the development of SCE across Asia and highlight the areas of potential collaboration between centres to advance the science of sarcoma.

show abstract

501O_PR Epidemiology, real world treatment and outcomes of 423 patients (pts) with angiosarcoma (AS) in Asia: A report from the Asian Sarcoma Consortium (ASC)

Cited by 2 publications

References 0 publications

The Asian Sarcoma Consortium Sarcoma Preceptorship Program: A Program Evaluation Study Utilizing the Kirkpatrick Model (Level 1 and 2)

The Asian Sarcoma Consortium Sarcoma Preceptorship Program: A Program Evaluation Study Utilizing the Kirkpatrick Model (Level 1 and 2)

Soft tissue sarcoma in Asia

Contact Info

Product

Resources

About